

Company name: Visionix Ltd. * Website: www.visionix.com * CEO name: Dr. Marc Abitbol * * Select a CATEGORY: Medical Devices *

Executive Summary / Investment Rationale Visionix develops ophthalmic diagnostic technologies spanning multimodal platforms and OCT. The company addresses growing demand for earlier, richer eye-care diagnostics. It has built a global commercial footprint, expanded through innovation and partnerships, and now enters a new phase through its merger with Revenio. Leadership combines entrepreneurial drive, technology vision, and international execution. **Core Technology** Visionix combines multimodal diagnostic capabilities with advanced imaging, including OCT, into integrated platforms designed for clinical relevance and workflow efficiency. Its uniqueness lies in merging complementary technologies, engineering depth, and user-oriented design to deliver scalable diagnostic systems that improve decision-making in eye care. **Product Profile/Pipeline** The portfolio includes multimodal diagnostic systems and OCT solutions serving ophthalmology and eye-care professionals. The market potential is supported by rising demand for earlier detection and better clinical integration. Key milestones include platform expansion, broader market adoption, and strategic opportunities for collaboration, distribution, and technology integration within the combined Visionix-Revenio group. **Business Strategy** Visionix drives revenue through technology-led product sales while exploring recurring models such as Hardware-as-a-Service. The strategy combines innovation, market access, and long-term customer value. Short-term growth comes from product expansion and installed-base development; long-term growth is expected from recurring service models, platform integration, and the strategic scale created by the Revenio merger. **What's Next? R&D, Preclinical / Clinicals, Organizational Plans, Financial Plans** Next steps include continued R&D in advanced diagnostics and platform integration, accelerated commercialization, and organizational alignment following the merger with Revenio. The combined company aims to strengthen its position as a leading independent diagnostic player by pairing Israeli creativity and speed with Finnish management discipline, operational rigor, and global scaling capabilities.